Figure S6 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer

This is a Quantitative Study study.

Key Points

vg9vd2 t cells show significant antitumor activity in triple-negative breast cancer, indicating a promising therapeutic role.
Enhancement is linked to anti-pd-l1 therapy and the restoration of activation defects by btn3a.
This study emphasizes the critical function of vg9vd2 t cells in cancer immunotherapy.
The findings support further exploration of t cell-based therapies in triple-negative breast cancer.

Observational analysis reveals enhanced antitumor activity in tnbc with vg9vd2 t cells, suggesting therapeutic potential with btn3a.

Vg9Vd2 T cells are transcriptionally armed for type–I antitumor cytotoxic activity in untreated TNBC (related to Figure 2).

No takes yet. Share an insight, caveat, or question.

Fattori et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share